Ant International Powered Over 2 Billion Transactions in its Core Emerging Markets in 2025, Expanding AI Payments and Digital Commerce Tools for Inclusive Growth
13.1.2026 11:15:00 CET | Business Wire | Press Release
Ant International supported over 2 billion digital cross-border transactions in 2025 for merchants in its core emerging markets including Southeast Asia (SEA), South Asia, the Middle East and Latin America (LATAM), as the company builds out a broader range of AI-powered digital financial and commerce solutions tailored to these regions’ diverse needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113850175/en/
Alipay+ now connects more than 1.8 billion user accounts across 40 international payment partners to merchants across more than 100 markets
Ant International is focused on improving access to payments, credit, digital banking and cross-border connectivity in fast-growing but fragmented digital economies. The company currently serves more than 150 million merchants globally, 90% of which are SMEs.
“In the world’s fastest growing emerging markets, real-world, trusted and scalable adoption of AI and other new technologies can unlock entirely new growth opportunities for businesses big and small,” said Douglas Feagin, President of Ant International. “It is time for fintech innovators to convert access into real growth momentum. We will work even harder to put AI-powered digital payments, financing, commerce and cross-border solutions on the ground for entrepreneurs and communities with ever lower cost and ever stronger safety and security guardrails.”
Digital Inclusion multiplies growth
Payment digitalisation and integration is crucial for business success in emerging markets:
- Through Alipay+ and Antom, online and offline merchants accept a variety of QR, mobile and card payments
- With strong leadership across Asia, Ant International will expand this connectivity to the Middle East and LATAM
- Alipay+ will also empower e-wallet and super-app development in more markets to support the growth of local payments and fintech ecosystems.
Access to banking and financing remains a key challenge for SMEs:
- Bettr expanded credit services for over 30 million SMEs and individuals, and expanding across LATAM following a strategic investment in R2, the leading embedded lending infrastructure company in LATAM.
Putting on the Ground Effective and Trusted Innovation
Ant International is laser-focused on building trusted FinAI technologies. In 2025, Ant international open-sourced its proprietary Falcon Time-Series Transformer (TST) AI model, which enhanced AirAsia’s FX risk management and reduced its hedging costs by up to 40%.
While investing in cutting-edge fintech innovations, Ant International is also focused on supporting effective, safe, and controlled adoption of AI in commerce to help merchants achieve measurable and scalable results.
- Antom, our flagship merchant payment services, now help clients to cut payment integration time by as much as 95% with Antom Copilot, its pioneering payment agent. Antom Payment Orchestration (APO) service builds one-integration, all-around payment access for merchants with smart routing to improve payment success rates. Overall, Antom clients recorded a 75% growth outside China.
- Combining localised expertise with adaptive AI tools, our full-suite payments platforms 2C2P in SEA and MultiSafePay in Europe now support a broad range of businesses from regional airline, O2O, e-commerce leaders to local SMEs.
- EPOS360, a pioneering AI-powered SME app, integrates practical AI tools with POS system, payments, banking, financing, and growth operations for small businesses.
- WorldFirst, extending proven AI capabilities in FX management, risk control and customer service, has evolved into a 360-degree global digital account service to offer payment and financial management tools across 200+ markets and 130+ e-marketplaces.
Adoption of AI has to be premised on a strong security foundation. Ant International's SHIELD 3-in-1 risk management transformer model integrates graph, sequence and tabular modalities in protecting our clients and our businesses. It has achieved 95% precision in identifying high-risk transactions, and boosted payment success rates by as much as 13.5%.
Interoperability and Real-Time Payment (RTP) Efficiency unlocks Future of Commerce
Cross-border interoperability across diverse modes of payments, remains a key driver of trade, tourism and economic growth. Alipay+ currently connects more than 1.8 billion user accounts across 40 international payment partners to merchants across more than 100 markets. It is the world’s largest cross-border mobile payment public-private partnership, collaborating with 11 national QR networks globally. Through a partnership with Mastercard, Alipay+ partners – AlipayHK, GCash and Kakao Pay – can tap-to-pay via NFC across Mastercard-enabled merchants.
Ant International’s Platform Tech enables highly efficient cross-border fund transfers by processing over US$600 billion via blockchain, operating 24/7 with more than 95 percent completed on the same day. In addition, Ant International and SWIFT recently pioneered the first bank-to-wallet payment, opening the opportunity for global bank customers to send funds directly to mobile wallets.
Southeast Asia Champions Inclusive Fintech Success
In SEA, where Ant International has worked with local partners for more than a decade, SMEs have seen measurable impact to their businesses.
Regional FinAI Development:
- Alipay+ continues to support the development of the region’s largest mobile platforms, including DANA (Indonesia), GCash (the Philippines), TrueMoney (Thailand) and TNG Digital (Malaysia), transforming financial transactions for hundreds of millions of consumers and businesses.
- In 2025, 3 regional apps began to build own AI-driven super app with the support of Ant International's AI-as-a-Service platform, the GenAI Cockpit.
- Alipay+ Voyager, an AI travel services agent, was launched successfully in 6 apps across Asia.
Interoperability:
- Alipay+ partners with 5 national QR payment networks in ASEAN – in Singapore and Malaysia, travellers spent 2.7 times and 2 times more respectively via SGQR and DuitNow QR, bringing real economic value to SMEs. In Malaysia, travellers have used their home e-wallet or bank app to make payment at more than 360,000 SMEs across the country, enabling them to benefit from tourism growth.
- SEA super apps, like GCash, are the world's first to begin wallet-to-card mobile payment integration with Alipay+'s NFC partnership with Mastercard to combine their merchant QR and POS networks.
Trade and Commerce:
- 2C2P under Antom saw 38% YoY growth in transaction volume for merchants in SEA, driven by growth in the e-commerce, airline, OTA, and retail sectors, and marked by strong momentum in Thailand, Vietnam, Indonesia, and the Philippines.
- WorldFirst, with new entries into Malaysia and Thailand, saw nearly 40% growth in transaction value in 2025 as more SEA SMEs take on global e-commerce.
Inclusive Finance:
- Bettr provides credit tech solutions to four leading SEA mobile wallets, driving a 184% increase in user base.
- ANEXT Bank in Singapore saw a six-fold increase in cross-border transaction volumes, with 69% of its customers being micro-businesses.
“As digital economies across Southeast Asia and other developing markets continue to scale, Ant International remains focused on enabling access and fostering shared prosperity. We work with partners, governments and businesses to promote growth that is inclusive, sustainable and globally connected,” Feagin said.
Note: All data are year-on-year comparisons for 2025 vs 2024
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260113850175/en/
Contacts
For media enquiries, please contact
Ant International PR Team
pr@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom